The company will be eligible to receive an upfront cash payment of $150M in royalty interest financing and $50M in debt upon the potential FDA approval of taletrectinib and an option for a second ...
Companies in the Energy sector have received a lot of coverage today as analysts weigh in on Kimbell Royalty Partners (KRP – Research Report) and Kinder Morgan (KMI – Research Report).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback